Skip to main content
. 2024 Jan 26;45(7):3379–3387. doi: 10.1007/s10072-024-07308-y

Fig. 2.

Fig. 2

Cost needed to treat (CNT) of AHSCT and HE-DMTs to obtain one patient free from relapse activity over a 2-year (a) and 5-year period (b). Estimates of relapse-free survival (RFS) for AHSCT and HE-DMTs are extrapolated from prospective or cohort studies on BEAM-based AHSCT and RCTs and extension studies, respectively (details in the “Materials and methods” section)